This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

AVANIR Pharmaceuticals' CEO Discusses F1Q12 Results - Earnings Call Transcript

AVANIR Pharmaceuticals, Inc. ( AVNR)

F1Q12 Earnings Call

February 7, 2012 4:30 PM ET

Executives

Ian Clements – IR

Keith Katkin – President and CEO

Christine Ocampo – VP, Finance

Joao Siffert – SVP, Research and Development

Randall Kaye – SVP, Clinical Research and Medical Affairs and Chief Medical Officer

Analysts

Charles Duncan – JMP Securities

Ritu Baral – Canaccord

Thomas Wei – Jefferies

Christopher James – MLV & Company

Carol Werther – Summer Street

Gregory Wade – Wedbush

Presentation

Operator

Good afternoon. My name is Nathalie and I will be your conference operator today. At this time, I would like to welcome everyone to the AVANIR Fiscal 2012 First Quarter Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session.

(Operator Instructions)

Thank you. Mr. Ian Clements, you may begin your conference.

Ian Clements

Thank you, operator and good afternoon, everybody. I’d like to welcome you to our conference call to discuss our financial and operating results for fiscal 2012 first quarter. Today is the one-year anniversary of the commercial launch of NUEDEXTA. Hence this is an opportune time to discuss the success of our initial launch phase and the strong momentum heading into 2012.

We have recently undertaken several initiatives to help accelerate revenue growth and deliver meaningful returns to our shareholders. To discuss our results and these initiatives, I’m joined by Keith Katkin, President and Chief Executive Officer, who will provide a strategic overview of our performance, Christine Ocampo, Vice President of Finance, who will provide additional details on our financial performance during the quarter and Dr. Joao Siffert, Senior Vice President, Research and Development who will provide an R&D update. For the Q&A portion of today’s call, we will also be joined by Dr. Randall Kaye, Chief Medical Officer.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs